HELP YOUR PATIENTS REDUCE THEIR RISK OF FUTURE CARDIOVASCULAR EVENTS

40%

100

CV

Ris

k R

educ

tion

LDL-C Reduction (mg/dL)

20%

0%806040200

LDL-C: ONE OF THE MOST CRITICAL FACTORS IN REDUCING CV RISK

CTTC meta-analysis linking that a 1mmol/L reduction in LDL-C amounts to just over 20% reduction in CV events.2

A linear relationship was demonstrated between LDL-C reduction and CV event reduction in risk over 25 years of studies.2,3

Systematic reviews and large trials have found that lowering cholesterol in people at high risk of coronary events substantially reduces the incidence of major coronary and vascular events.2

While certain cardiovascular disease (CVD) risk factors such as a family history of disease or age cannot be changed, high LDL-C is one of the most important and impactful modifiable risk factors.1 It is important you ensure your patients understand this.

Lowering LDL-C = Lower CVD risk3,4

MIs AND STROKES OCCUR EVERY YEAR8

30 millionCVDs ARE THE NUMBER ONE CAUSE

OF DEATH GLOBALLY.7 OVER

SURVIVING AN INITIAL CARDIOVASCULAR EVENTIS JUST THE BEGINNING

PATIENTS WILL SUFFERANOTHER EVENT

1in3

If your patient still has elevated LDL-C, despite

the use of statins and other traditional lipid-lowering therapies, THEY REMAIN

AT RISK FOR SUBSEQUENT CARDIOVASCULAR

EVENTS.6,7,8

HIGH LOW-DENSITY LIPOPROTEIN

CHOLESTEROL (LDL-C) is one of the most dangerous risk factors for MI or stroke.5

Work with your patients to lower their LDL-C

and reduce their risk of future events.

CARDIOVASCULAR DISEASE: A GROWING HEALTH CONCERNCVD is a growing health concern, and the prevalence is expected to rise, in part, due to the aging global population.6

Your patient does not want another myocardial infarction (MI) or stroke. Neither do you.

MYOCARDIAL INFARCTIONS (MI) AND STROKES OCCUR EVERY YEAR

+32.4 millionCARDIOVASCULAR DISEASES (CVDS) ARE THE

NUMBER ONE CAUSE OF DEATH GLOBALLY

SURVIVING AN INITIAL CARDIOVASCULAR EVENTIS JUST THE BEGINNING

PATIENTS WILL SUFFERANOTHER EVENT

1in3

is one of the most dangerous risk factors for MI or stroke

THEY REMAIN AT RISKFOR SUBSEQUENT

CARDIOVASCULAR EVENTS

If your patient has suffered previous MI or stroke and still

has elevated LDL-C, despite use of high-intensity statins,

HIGH LOW-DENSITY LIPOPROTEINCHOLESTEROL (LDL-C)

Work with them to lower their LDL-C and reduce their risk of

future events

HELP YOUR PATIENTS MANAGE THEIR CARDIOVASCULAR HEALTH

1 in 3NEARLY

WILL HAVE A SUBSEQUENT CARDIOVASCULAR EVENT.8

Your patient is still at high risk if high LDL-C is not addressed, despite statins and other traditional lipid lowering therapies. The introduction of statins resulted in significant progress in cardiovascular care. However, even when taking high-intensity statins, many patients remain at risk of another major CV event.9,10

The growing unmet needs in treating hyperlipidaemic patients include the reduction of the patients’ risks for CVD and the consequent reduction of the occurrence of CV events, confirming the necessity of intensifying lipid-modifying management.11

HIGH LDL-C: ARE YOUR PATIENTS STILL AT RISK?

Statins alone are not enough for everyone9

Residual risk remains even in those receiving treatment with high-intensity statins. The lowest achieved LDL levels translate

to the lowest CV risk.4,9

DO NOTACHIEVE>70% <70mg/dL

of very high-risk patients13

the optimal LDL-C goal13

Not switching to a more potent drug when necessary

A lack of follow-up after initiation of treatment

Inadequate dosing

Suboptimal hyperlipidaemia management is evidenced worldwide by: the failure of large numbers of patients to achieve LDL-C targets and the failure of patients in high-risk or very-high risk categories to attain LDL-C goals.12

Reasons for poor attainment of treatment goals can include:12

Lowering LDL-C addresses the risk for a second MI or stroke—and helps ease your patient’s fear of another event.

Through suggested lifestyle changes and appropriate medications, you and your nursing staff are the key to addressing the risk of a future MI or stroke with your patient.

MANAGING LDL-C REDUCES MI AND STROKE RISK

It is important to routinely re-evaluate LDL-C levels. If you or your nursing staff notice a patient’s LDL-C levels remain high, even with a statin or other traditional lipid-lowering therapy, you might want to explore other innovative options.14

YOU ARE A TRUSTED RESOURCE. HELP PATIENTS LOWER LDL-C WITH THE RIGHT THERAPIES.

A substantial percentage of patients do not achieve target LDL-C despite maximal statin therapy.11

Help lower their LDL-C by prescribing them the right therapies. Your patients rely on you to tell them

about treatments to improve their health and address

their concerns about elevated LDL-C.

LDL-C can be further reduced. Your patients don’t want an emergency. If they’re at high risk for another CV event, talk to them about adding additional treatments to their statin therapy.

When it comes to LDL-C, the lower the better. Some high-risk patients need more than a statin or other traditional lipid-lowering therapy.9

Innovative therapies can help to further reduce LDL-C and reduce patients’ risk of MI or stroke.9,14

Referencias1. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.2. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670-81. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21067804. Last accessed August 2018.3. Ference B, Ginsberg H, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease European Heart Journal (2017) 38, 2459–2472 doi:10.1093/eurheartj/ehx144.4. Boekholdt et al. Very low levels of atherogenic lipoproteins and risk of cardiovascular events; a meta-analysis of statin trials J Am Coll Cardiol. 2014 August 5; 64(5): 485–494. doi:10.1016/j.jacc.2014.02.615.5. Odden MC, Coxson PG, Moran A., et al. The impact of the aging population on coronary heart disease in the disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-2472. United States. Am J Med. 2011 Sep;124(9):827-33.e5.6. World Health Organization. Cardiovascular diseases (CVDs) Key Facts. 17 May 2017. Available at:http://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed August 2018.7. World Health Organization. Prevention of Recurrences of Myocardial Infarction and Stroke Study The PREMISE programme:country projects. Available at: http://www.who.int/cardiovascular_diseases/priorities/secondary_prevention/country/en/index1.html. Last accessed August 2018.8. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients atrisk of or with atherothrombosis. JAMA.2010;304:1350-1357.https://www.ncbi.nlm.nih.gov/pubmed/208056249. Fox K, Kostev K, Vultee C, et al. Lack of low-density lipoprotein cholesterol (LDL-C) goal attainment among high-riskpatients using high or moderate intensity statin therapy in Germany. Eur Heart J. 38. 10.1093/eurheartj/ehx502.P2320.10. Sampson, UK., et al. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence,etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012 Feb;14(1):1-10. 11. David D. Waters, Carlos Brotons, Cheng-Wen Chiang. Circulation AHA. “Lipid Treatment Assessment Project 2.”12. Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M. (2016). Unmet need in the hyperlipidaemia population with high riskof cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovasc Disord. 2016 Apr 26;16:74. 13. Gitt A, Lautsch D, Ferrieres J, et al. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients. Atherosclerosis. 2016 Dec;255:200-209.14. Sabatine et al. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels - A Meta-analysis; JAMA Cardiol. doi: 10.1001/jamacardio.2018.2258.

Visit www.emergencycholesterol.comfor more information

PR-NA-ARE-000017 Sep 18

Amgen Middle East FZ-LLC Business Central Tower A, 2007 P.O Box 502607, Dubai, UAE